Stockreport

Lyell Immunopharma: Potential Solid Tumor Targeting With CAR-T And TIL [Seeking Alpha]

Lyell Immunopharma, Inc.  (LYEL) 
PDF Results from phase 1 study using LYL845 for the treatment of patients with relapsed/refractory metastatic or advanced melanoma, NSCLC, and colorectal cancer are expecte [Read more]